On Tuesday, Combat Sports Anti-Doping (CSAD) announced that Joilton Lutterbach was suspended for two years for violating UFC anti-doping policy. Lutterbach tested positive for the presence of 3a-hydroxy-2a-methyl-5a-androstan-17-one, a metabolite of drostanolone, through a urine sample collected on June 8.
Joilton Lutterbach was supposed to make his UFC debut against Shara Magomedov on June 22nd at UFC Saudi Arabia. He was removed two days before the event due to the positive test.
CSAD stated, “Lutterbach admitted to extensive use of drostanolone in the months before he was signed to a UFC contract. Upon being added to the UFC Anti-Doping Program, all athletes are required to declare the use of any prohibited substances they have used over the last 12 months. An athlete who makes such a declaration will not be deemed to have committed a violation, but depending on the substance and circumstances, may be required to refrain from competition for a period of at least 180 days and provide at least two negative sample results. Lutterbach did not declare his use of drostanolone on his onboarding declaration form while admitting that he realized he should have done so.”
CSAD notified Joilton Lutterbach in writing of the adverse findings on June 23, 2024. Therefore, Lutterbach will be eligible to return to the octagon from June 23, 2026. However, he was released from UFC due to the failed drug test.